Phibro Animal Health (NASDAQ:PAHC – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Friday.
Several other equities research analysts also recently issued reports on the company. Barclays increased their price target on Phibro Animal Health from $13.00 to $20.00 and gave the stock an “underweight” rating in a report on Tuesday, November 12th. JPMorgan Chase & Co. started coverage on Phibro Animal Health in a research note on Tuesday, September 10th. They set a “neutral” rating and a $22.00 target price for the company. Finally, Bank of America lifted their price target on shares of Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research note on Friday, August 30th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $16.50.
View Our Latest Stock Report on Phibro Animal Health
Phibro Animal Health Trading Up 1.3 %
Institutional Trading of Phibro Animal Health
A number of institutional investors have recently made changes to their positions in PAHC. CWM LLC lifted its position in Phibro Animal Health by 89.8% during the 2nd quarter. CWM LLC now owns 2,188 shares of the company’s stock worth $37,000 after buying an additional 1,035 shares in the last quarter. Quantbot Technologies LP bought a new stake in Phibro Animal Health during the third quarter worth about $70,000. nVerses Capital LLC acquired a new position in Phibro Animal Health during the third quarter valued at approximately $70,000. China Universal Asset Management Co. Ltd. grew its stake in Phibro Animal Health by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock valued at $88,000 after purchasing an additional 1,522 shares in the last quarter. Finally, Summit Securities Group LLC bought a new position in Phibro Animal Health in the second quarter valued at approximately $83,000. Institutional investors own 99.34% of the company’s stock.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.
Recommended Stories
- Five stocks we like better than Phibro Animal Health
- How to Calculate Return on Investment (ROI)
- Trinity Capital CEO on Leading Private Credit’s High-Yield Growth
- What is the Australian Securities Exchange (ASX)
- Lululemon Surges On Q3 Report: Analysts Step in To Support Market
- Trading Stocks: RSI and Why it’s Useful
- 10 Safe Investments with High Returns
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.